Clinical Trial: The Chinese Hypertrophic Cardiomyopathy Study(CHCS)

Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Observational

Official Title: The Chinese Hypertrophic Cardiomyopathy Study(CHCS)

Brief Summary: Hypertrophic cardiomyopathy (HCM) is one of the most common inherited cardiac diseases, with a prevalence of ∼0.2%. The disease affects all age groups, with marked clinical heterogeneity, ranging from a normal life span without symptoms to poor outcomes such as sudden cardiac death (SCD), advanced heart failure, or stroke.

Detailed Summary: The investigators' research group determined the prevalence of hypertrophic cardiomyopathy in China via epidemiologic investigation was performed in 8080 adults from nine communities across nine provinces in China from October 2001 to February 2002, and started to investigate the Genotype-phenotype correlations by then. The investigators not only found out the hot mutations in Chinese and new related gene which were different from other races, but also uncovered the presence of multiple rare variants in sarcomere genes is a risk factor for malignant outcomes in HCM. The investigators intent to observe and refining the clinical and genetic feature in Chinese patients of HCM and reveal the risk factors for prediction model of prognosis.
Sponsor: China National Center for Cardiovascular Diseases

Current Primary Outcome: Primary mortality [ Time Frame: Through study completion, an average of 5 years ]

The mortality due to SCD


Original Primary Outcome: Same as current

Current Secondary Outcome:

  • Cardiovascular mortality except SCD [ Time Frame: Through study completion, an average of 5 years ]
    The incidence rate of cardiovascular mortality except SCD
  • Heart failure(level III or IV in New York Heart Association ) [ Time Frame: Through study completion, an average of 5 years ]
    The incidence rate of heart failure(level III or IV in New York Heart Association )
  • Stroke [ Time Frame: Through study completion, an average of 5 years ]
    The incidence rate of stroke,including cerebral infarction and hemorrhage
  • Malignant arrhythmia [ Time Frame: Through study completion, an average of 5 years ]
    The incidence rate of malignant arrhythmia


Original Secondary Outcome: Same as current

Information By: China National Center for Cardiovascular Diseases

Dates:
Date Received: January 26, 2016
Date Started: March 2016
Date Completion: March 2020
Last Updated: February 25, 2016
Last Verified: February 2016